Status:
RECRUITING
Chronic Kidney Disease Registry Platform Study
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Kidney Diseases
Eligibility:
All Genders
18+ years
Brief Summary
This is a multicenter, prospective, observational registry platform study which is designed to establish a CKD registry platform by collecting data on the demographics, etiology and staging, clinical ...
Detailed Description
Chronic Kidney Disease (CKD) is characterized by its high prevalence, low awareness, poor prognosis, and high medical costs, which seriously jeopardize human health. High-risk factors such as severe p...
Eligibility Criteria
Inclusion
- Registry Platform Study Basic Inclusion \&
Exclusion
- Inclusion Criteria:
- Aged ≥ 18 years at enrollment;
- Patients who meet the diagnostic criteria for CKD;
- Last eGFR ≥ 20 and \< 90 mL/min/1.73 m2 (with the CKD-EPI formula) within 12 months prior to enrollment;
- Patients who voluntarily participate in this study and has signed and dated the informed consent form for the study;
Key Trial Info
Start Date :
November 28 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2028
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT06117852
Start Date
November 28 2023
End Date
November 30 2028
Last Update
December 16 2025
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Baotou, China
2
Research Site
Beijing, China
3
Research Site
Beijing, China
4
Research Site
Changsha, China